RB001 Gene Therapy Study in Children With SHANK3-related Phelan-McDermid Syndrome (PMS)

An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluating the Safety, Tolerability and Preliminary Efficacy of a Single Intracerebroventricular Injection of RB001 for the Treatment of SHANK3-related Phelan-McDermid Syndrome.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07014020

Enrollment

Registered

2025-06-10

Start date

2025-06-16

Completion date

2027-12-31

Last updated

2026-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phelan-McDermid Syndrome, SHANK3 Haploinsufficiency

Keywords

AAV, SHANK3, Phelan-Mecdermid Syndrome, 22q13.3 deletion syndrome

Brief summary

This is an open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of RB001 administered via intracerebroventricular (ICV) injection in pediatric with SHANK3 related Phelan-McDermid Syndrome. Clinical data will be evaluated for safety, tolerability, and preliminary efficacy of RB001 in participants with SHANK3 related PMS.

Detailed description

SHANK3-related Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder primarily caused by a deletion of chromosome 22q13 or a mutation of the SHANK3 gene. The syndrome is characterized by intellectual disability and language impairment. The SHANK3 protein is part of the postsynaptic density complex and participates in postsynaptic signal transduction and synaptic development, serving as a critical structural protein for central nervous system development and functional maintenance. SHANK3 deficiency leads to abnormal neuronal development and is the primary cause of PMS. The estimated global prevalence is approximately 1/15,000. Clinical manifestations include global developmental delay, particularly severe language delay, autism-like behaviors, hypotonia, and potentially epilepsy. Currently, there are no effective treatments for this condition. RB001 is developed by Shenzhen Reborngene Therapeutics Co., Ltd. for the treating of Phelan-McDermid Syndrome. RB001 utilizes the Adeno-Associated Virus (AAV) vector to deliver an optimized SHANK3-minigene via intracerebroventricular (ICV) injection. Nonclinical studies have demonstrated that a single ICV injection of RB001 could restore SHANK3 mRNA and protein expression in the target region of central nervous system of the SHANK3-mutant mouse models, as well as the restore of motor deficits, stereotypical behaviors, and reduced exploratory behaviors and neuronal function. A target of 8 pediatric participants aged 3 to 18 years will be treated. All participants will be followed for safety, tolerability and preliminary efficacy after the date of treatment with RB001.

Interventions

GENETICRB001

The study will enroll up to 2 cohorts, evaluating a starting dose plus a higher or lower dose

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluating the Safety, Tolerability and Preliminary Efficacy of a Single Intracerebroventricular Injection of RB001

Eligibility

Sex/Gender

ALL

Age

3 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Age ≥3 years and \<18 years (at the time of signing informed consent), any gender * Genetic test and clinical confirmed diagnosis of SHANK3-related PMS * Meets diagnostic criteria for moderate or more severe Autism Spectrum Disorder (ASD) * Intelligence Quotient (IQ) score \<70 or Developmental Quotient (DQ) (excluding gross motor) average score \<70 * Willing to provide biological samples required for the study (e.g., blood, urine) * Consent to hospitalization for intracerebroventricular injection surgery * The holders of parental authority who are able to understand and willing to comply with study requirements and procedures, voluntarily participating and signing the informed consent

Exclusion criteria

A pediatric participant who meets any of the following criteria will be excluded from this study: * Previous or current participation in other PMS drug clinical trials or other AAV gene therapy clinical studies * Has known allergic constitution, including allergy or hypersensitivity to prednisone acetate, other glucocorticosteroids, their excipients, or local anesthetics * Subjects with status epilepticus within 3 months prior to enrollment * Subjects requiring invasive or non-invasive ventilatory support * Serum anti-AAV neutralizing antibody titer \>1:200 * Significant laboratory abnormalities: alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT) with any value above the upper limit of normal; total bilirubin above the upper limit of normal; creatinine ≥159 μmol/L; hemoglobin (Hb) \<80 g/L; prothrombin time (PT) prolonged by ≥3 seconds; activated partial thromboplastin time (APTT) prolonged by ≥10 seconds; fasting blood glucose ≥7.0 mmol/L; glycated hemoglobin (HbA1c) ≥6.5%; platelets (PLT) \<100×10\^9/L * Subjects with liver disease or history of heart disease that may pose drug-related risks as assessed by the investigator * Subjects deemed unsuitable for intracerebroventricular administration or with other special circumstances as assessed by the investigator * Positive for human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, active TORCH virus infection, or active Epstein-Barr virus infection * Concomitant use of any of the following medications within 90 days prior to administration, or planned immunosuppressive treatment within 3 months after starting the trial, except for prophylactic medications specified in the protocol (cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin, rituximab, etc. ) * Other conditions deemed unsuitable for participation in this study by the investigator

Design outcomes

Primary

Measure	Time frame	Description
To evaluate the safety and tolerability of a single intracerebroventricular injection of RB001 through week 52	52 weeks	Types, severity, and incidence of adverse events (AEs) and serious adverse events (SAEs) within 52 weeks after RB001 injection

Secondary

Measure	Time frame	Description
To evaluate the changes on Clinical Global Impression Scale - Severity (CGI-S) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes from baseline at weeks 12, 26, and 52 after RB001 injection. Clinical Global Impression Scale (CGI) severity item provided with a seven-point scale of severity of patient's clinical condition (1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.)
To evaluate the changes on Clinical Global Impression Scale - Improvement (CGI-I) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes from baseline at weeks 12, 26, and 52 after RB001 injection. Clinical Global Impression Scale (CGI) Improvement item provided with a seven-point scale of improvement of patient's clinical condition (1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.)
To evaluate the changes on Patient's Global Impressions of Improvement (PGI-I) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes from baseline at weeks 12, 26, and 52 after RB001 injection. The PGI-I consists of a single item in which participants or their parents rate the participant's overall health status relative to baseline using a 7-point scale, scale anchors correspond to those of the CGI-I: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse.
To evaluate the changes on Childhood Autism Rating Scale (CARS-2) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes from baseline at weeks 12, 26, and 52 after RB001 injection. The CARS-2 is a clinician-completed rating scale based on direct observation of the child's behavior in standardized contexts. It comprises 15 descriptive items assessing domains including relating to people, imitation, emotional response, body use, object use, and adaptation to change. Each item is scored from 0 to 4, with 0 indicating no abnormality and 4 indicating severe abnormality. The rater integrates behavioral observations with an overall clinical impression of severity to compute a total score ranging from 15 to 60, and converted into a T-score through norm-referenced comparison. Higher T-scores indicate a higher level of autism severity, and a T-score \>40 indicates the presence of moderate or above autism-related symptoms.
To evaluate the changes on Autism Behavior Checklist (ABC) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes from baseline at weeks 12, 26, and 52 after RB001 injection. The ABC is a clinician-rated instrument based on direct observation of the child's behavior. It includes 57 items distributed across five domains: sensory, relating, body and object use, language, and self-help behavior. Each item is rated as either "yes" (present) or "no" (absent), based on whether the behavior is observed. The total score is calculated by summing the weighted scores of items endorsed as "yes" (item weights vary from 1 to 4). Higher total scores indicate greater autism-related behavioral impairment. The score is interpreted as follows: total \< 53 = negative (low risk), 53-67 = suspicious (moderate risk), and ≥ 68 = positive (high clinical concern for autism spectrum disorder).
To evaluate the changes on Griffith developmental assessment scale - Chinese (GDS-C) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes of developmental trajectories from baseline at weeks 12, 26, and 52 after RB001 injection, the Griffiths Developmental Assessment Scale - Chinese Version (GDS-C) is accessed by certified examiners. The scale evaluates 240 age-standardized tasks across six domains (Locomotor, Personal-Social, Language, Eye-Hand Coordination, Performance, and Practical Reasoning). Tasks are scored 0 or 1 (1=pass, 0=fail), with raw scores converted to Developmental Quotients (DQ) using China-specific norms (2020 revision). DQ\<85 suggests potential mild developmental delay, while a multi-domain DQ\<70 indicates significant developmental delay.
To evaluate the changes on Peabody developmental motor scales - 2nd Edition (PDMS-2) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes of developmental trajectories from baseline at weeks 12, 26, and 52 after RB001 injection. The PDMS-2 is a standardized, norm-referenced clinical tool used to assess gross and fine motor development in children. Certified clinicians administer age-appropriate items across five domains: reflexes, stationary, locomotion, grasping, and object manipulation. each item is scored based on the child's level of performance, and raw scores are converted to standard scores, percentiles, and composite motor quotients including the gross motor quotient, fine motor quotient, and total motor quotient. Motor quotients are norm-referenced with a mean of 100 and standard deviation of 15. A motor quotient \< 85 indicates potential mild motor delay, while a quotient \< 70 suggests significant motor developmental impairment.
To evaluate the changes on Wechsler Preschool and Primary Scale of Intelligence (WPPSI) or Wechsler Intelligence Scale for Children (WISC) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate cognitive changes from baseline at weeks 12, 26, and 52 after RB001 injection, the Wechsler Intelligence Scales are administered based on baseline age: WPPSI for subjects aged 2.5-7.7 years at screening, WISC for subjects aged 6-16 years at screening. the certified neuropsychologist conducts assessments under standardized conditions and assigns scores based on five scales (Verbal Comprehension, Visual Spatial, Fluid/Quantitative Reasoning, Working Memory, Processing Speed) to derive a Full Scale IQ. Scores are norm-referenced (mean=100, SD=15), with higher values indicating superior cognitive ability. IQ\<85 suggests potential mild cognitive delay, while IQ\<70 indicates significant cognitive delay.
To evaluate the changes on Adaptive Behavior Assessment System-Second Edition (ABAS-2) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes of functional adaptive behaviors from baseline at weeks 12, 26, and 52 after RB001 injection, the Adaptive Behavior Assessment System-Second Edition (ABAS-2) is administered. the rater (usually the Guardian) score the child's daily living skills across 10 domains (Communication, Self-Care, Social, etc.) using age-specific questionnaires. Items are scored 0-3 based on frequency of competent performance, and raw scores normalized to standard scores based on ages (mean=100, SD=15). The General Adaptive Composite (GAC) serves as the primary secondary endpoint. CAG \< 85 suggests potential mild delay, while CAG ≤ 70 indicates significant delay.
To evaluate the changes on Social Life Ability Scale For Infant-Junior Middle School Student (S-M) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate adaptive functioning from baseline at weeks 12, 26, and 52 after RB001 injection, the Social Life Ability Scale for Infants-Junior Middle School Students (S-M Scale) is administered. Parents or primary caregivers observe the child's daily behaviors and score 132 specific items across six functional domains (Independent Living Skills, Motor Abilities, Practical Task Performance, Communication Skills, Self-Management, and Socialization). Each item is scored 0 or 1 (1 = pass, 0 = fail) based on observed capability. The total score (0-132) is calculated by summing all items, with higher scores indicating better adaptive functioning. A standard score ≤9 (equivalent to a raw score ≤70; ≥2 SD below the norm) suggests significant impairment in social adaptive abilities.
To evaluate the changes on Child Behavior Checklist (CBCL) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate behavioral/emotional problems from baseline at weeks 12, 26, and 52 after RB001 injection, the Child Behavior Checklist (CBCL) is administered. Parents or caregivers rate the child's behaviors using 113+ problem items across empirically based syndromes (Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints, Social Problems, Thought Problems, Attention Problems, Rule-Breaking Behavior, and Aggressive Behavior). Each item is scored 0-2 (0 = not true, 1 = somewhat/sometimes true, 2 = very/often true). The total problem score (0-240) is calculated by summing all items, with higher scores indicating greater behavioral/emotional impairment. A T-score \>63 (\>90th percentile) suggests clinical concern, and \>70 (\>98th percentile) indicates. (T-scores (M = 50, SD = 10) are derived from normative samples)
To evaluate the changes on Children's sleep habits questionnaire(CSHQ) after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate sleep pattern changes from baseline at weeks 12, 26, and 52 after RB001 injection. The CSHQ is a validated parent-report screening tool used to assess sleep patterns and common sleep disturbances in children. Parents or primary caregivers rate their child's recent sleep behaviors across multiple domains, including bedtime resistance, sleep onset latency, sleep duration, night wakings, sleep anxiety, parasomnias, sleep-disordered breathing, and daytime sleepiness. The questionnaire consists of 45 items, each scored on a frequency scale based on how often the behavior occurred during the past week: 1 = frequently (5-7 times), 2 = sometimes (2-4 times), and 3 = rarely (0-1 times). The total score is computed using the established scoring criteria; higher total scores indicate more severe sleep problems.
To evaluate AAV viral load after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate viral load dynamics from baseline, at Day 7, Weeks 4, 8, 12, 26, and 52 after RB001 injection, blood samples will be collected at each time point. Viral load will be quantified using RT-qPCR. (Sampling will be discontinued if viral load falls below the lower limit of detection for three consecutive measurements.)
To evaluate AAV viral shedding after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate Viral shedding from baseline, and at Day 7, Weeks 4, 8, 12, 26, 52 after RB001 injection. Saliva, urine, and feces samples will be collected at each time point. Viral load will be quantified using RT-qPCR. (Sampling will be discontinued if viral load falls below the lower limit of detection for three consecutive measurements.)
To evaluate AAV binding and neutralizing antibodies after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate AAV binding and neutralizing antibodies (Abs) dynamics from baseline, and at Day 7, Weeks 4, 8, 12, 26, 52 after RB001 injection. blood samples will be collected at each time point. Antibodies will be quantified using ELISA (for binding Ab) and cell-coculture (for neutralizing Ab). (Sampling will be discontinued if tests results are negative for three consecutive measurements.)
To evaluate SHANK3 binding antibody after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate SHANK3 binding antibody (Ab) dynamics from baseline, and at Weeks 4, 8, 12, 26, 52 after RB001 injection. blood samples will be collected at each time point. Antibodies will be quantified using ELISA. (Sampling will be discontinued if tests results are negative for three consecutive measurements.)
To evaluate changes in T-cell responses against AAV and SHANK3 after a single intracerebroventricular injection of RB001 through week 52	52 weeks	To evaluate changes in T-cell responses against AAV and SHANK3 from baseline and at Weeks 26 and 52 after RB001 injection, blood samples will be collected at each time point. Antigen-specific T-cell responses will be quantified using ELISpot assays with peptide pools spanning AAV capsid and SHANK3 epitopes libraries.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 29, 2026